Clinical Trial: Nitroglycerin Infusion During Cardiac Surgery
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Nitroglycerin Infusion During Rewarming in Cardiac Surgery and Its Effects on Tissue Perfusion and Coagulation
Brief Summary:
Hypothermic cardiopulmonary bypass results in peripheral vasoconstriction and heparin trapping. Hypoperfusion and ischemic-reperfusion injury are associated with systemic inflammatory response, while insufficient and delayed neutralization of heparin by protamine may contribute to more blood loss during rewarming stage.
Nitroglycerin infusion, an NO-related vasodilator, is an established and effective treatment for unstable angina, myocardial infarction, congestive heart failure, and perioperative hemodynamic management for cardiac surgery. Therefore, we hypothesize that nitroglycerin infusion during rewarming corrects systemic ischemic stress and facilitates heparin neutralization in cardiac surgery.
Detailed Summary: A randomized clinical trial in a tertiary academic center in patients with cardiac surgery, to receive either nitroglycerin infusion dose of 0-0.1 mcg/kg/min, or 1-5 mcg/kg/min during rewarming in cardiopulmonary bypass.
Sponsor: Tri-Service General Hospital
Current Primary Outcome:
- Plasma lactate level [ Time Frame: one year ]
- Perioperative blood loss [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Mean arterial blood pressure [ Time Frame: one year ]To keep mean blood pressure 50-80 mmHg during cardiopulmonary bypass.
- Inotropic doses [ Time Frame: one year ]
- Time to extubation [ Time Frame: one year ]
Original Secondary Outcome: Same as current
Information By: Tri-Service General Hospital
Dates:
Date Received: July 10, 2013
Date Started: July 2013
Date Completion: July 2016
Last Updated: July 13, 2013
Last Verified: July 2013
